What does the PulmoCore 20 Gene Panel – PD-L1 22C3 at Metropolis Healthcare include?
It assesses 20 lung cancer–associated genes and measures PD-L1 expression using the 22C3 clone.
How does Metropolis Healthcare perform this panel?
Metropolis Healthcare uses high-depth NGS for gene mutation analysis and validated 22C3 immunohistochemistry for PD-L1 scoring.
Who should consider taking this test at Metropolis Healthcare?
Patients with confirmed or suspected lung cancer who need molecular and immunotherapy guidance should take this panel.
Is fasting required for the PulmoCore 20 Gene Panel at Metropolis Healthcare?
No fasting is required; the test uses tumor tissue samples as advised by the clinician.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to comprehensive genomic and PD-L1 evaluation.
Can this test at Metropolis Healthcare help guide immunotherapy decisions?
Yes, PD-L1 22C3 results help determine eligibility and potential response to checkpoint inhibitor therapy.
How accurate is the gene and PD-L1 analysis at Metropolis Healthcare?
Metropolis Healthcare ensures high precision through validated sequencing and IHC protocols with strict quality control.
Does this panel support long-term treatment planning at Metropolis Healthcare?
Yes, it provides actionable molecular and immunotherapy insights for personalized lung cancer management.